TG Therapeutics, Inc. (TGTX)
53.97
-2.03
(-3.62%)
USD |
NASDAQ |
Oct 16, 16:00
53.75
-0.22
(-0.41%)
After-Hours: 20:00
TG Therapeutics Cash from Investing (Quarterly) : 1.03M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.03M |
| March 31, 2026 | -9.864M |
| December 31, 2025 | -15.64M |
| September 30, 2025 | 46.36M |
| June 30, 2025 | -3.992M |
| March 31, 2025 | -12.93M |
| December 31, 2024 | 15.79M |
| September 30, 2024 | -9.334M |
| June 30, 2024 | 1.765M |
| March 31, 2024 | -9.255M |
| December 31, 2023 | -44.76M |
| September 30, 2023 | -30.23M |
| June 30, 2023 | 30.50M |
| March 31, 2023 | -6.168M |
| December 31, 2022 | 16.27M |
| September 30, 2022 | -2.99M |
| June 30, 2022 | 10.38M |
| March 31, 2022 | -43.67M |
| December 31, 2021 | 3.288M |
| September 30, 2021 | -0.631M |
| June 30, 2021 | -2.475M |
| March 31, 2021 | -0.514M |
| December 31, 2020 | -52.08M |
| September 30, 2020 | 14.91M |
| June 30, 2020 | 11.20M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.45M |
| December 31, 2019 | 0.004M |
| September 30, 2019 | -0.044M |
| June 30, 2019 | 0.457M |
| March 31, 2019 | -1.135M |
| December 31, 2018 | 0.238M |
| September 30, 2018 | -6.435M |
| June 30, 2018 | 5.585M |
| March 31, 2018 | 1.792M |
| December 31, 2017 | -28.01M |
| September 30, 2017 | 8.800M |
| June 30, 2017 | 4.998M |
| March 31, 2017 | 6.00M |
| December 31, 2016 | 11.48M |
| September 30, 2016 | 15.58M |
| June 30, 2016 | 1.414M |
| March 31, 2016 | -1.924M |
| December 31, 2015 | 2.478M |
| September 30, 2015 | 0.0766M |
| June 30, 2015 | -31.08M |
| March 31, 2015 | 3.843M |
| December 31, 2014 | -9.133M |
| September 30, 2014 | -0.0013M |
| June 30, 2014 | -9.218M |
| March 31, 2014 | -0.0032M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Krystal Biotech, Inc. | -161.58M |
| Vertex Pharmaceuticals, Inc. | -45.80M |
| SELLAS Life Sciences Group, Inc. | 0.00 |
| Travere Therapeutics, Inc. | -206.29M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 39.26M |
| Cash from Financing (Quarterly) | 0.085M |
| Free Cash Flow | 17.38M |
| Free Cash Flow Per Share (Quarterly) | 0.2478 |
| Free Cash Flow to Equity (Quarterly) | 38.09M |
| Free Cash Flow to Firm (Quarterly) | 51.57M |
| Free Cash Flow Yield | 0.20% |